



PRESS RELEASE

29 July 2024 14:50:00 CEST

AcouSort enters collaboration with US based cell therapy company

Establishing OEM partnerships is one of AcouSort's strategic cornerstones. Earlier this year, AcouSort announced that the company had initiated two AcouWash lease projects to partnering companies with the intent to explore the use of the AcouWash system for applications within flow cytometry and cell therapy production. AcouSort has now initiated yet another collaboration, this time with a US based company active in the cell therapy space.

The new collaboration starts out with a three-month lease of an AcouWash system where the partnering company will evaluate the performance and applicability of the technology in different steps of the cell therapy production process. By leasing the AcouWash system to partnering companies, AcouSort is able to provide potential OEM customers with the possibility of exploring AcouSort's technology and understanding its capabilities. This is a crucial first step for establishing new OEM collaborations.

"The opportunity for potential OEM customers to lease an AcouWash system is an efficient way to kickstart collaborations and to give our partners the ability to explore the technology themselves. The projects that were initiated earlier this year are progressing according to plan, and we look forward to getting this next collaboration up and running as well," says Agnes Michanek, Commercial Director at AcouSort.

FOR FURTHER INFORMATION ABOUT ACOUSORT, PLEASE CONTACT:

Torsten Freltoft, CEO

Telephone: +45 2045 0854

E-mail: torsten.freltoft@acousort.com

ABOUT ACOUSORT

AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company's Certified Adviser is Carnegie Investment Bank AB (publ).